Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
To compare the risks of 1-month all-cause, major bleeding (MB)-related and stroke-related readmissions and the associated hospital resource use and costs among patients previously hospitalized for nonvalvular atrial fibrillation (NVAF) and treated with warfarin, rivaroxaban, and dabigatran vs apixaban. Adult patients hospitalized with NVAF (any discharge diagnosis position) who received apixaban, warfarin, rivaroxaban, or dabigatran during hospitalization were identified from the Premier database (1 January 2013-30 June 2017) and grouped into respective cohorts. Propensity score matching was used to generate cohorts with similar characteristics. In regression analyses the risk of readmissions that occurred within 1 month of discharge were evaluated and the associated length of stay (LOS) and costs compared. NVAF patients treated with warfarin vs apixaban had significantly greater risk of all-cause (odds ratio [OR] = 1.05; confidence interval [CI] = 1.02-1.08; < .001), MB-related (OR: 1.28; CI: 1.16-1.42; < .001), and stroke-related (OR: 1.33; CI: 1.11-1.58; = .002) readmissions; for all readmission categories, average LOS was significantly longer and costs significantly higher for warfarin treated patients. NVAF patients treated with rivaroxaban versus apixaban had significantly greater risk of all-cause (OR: 1.06; CI: 1.02-1.09; = .001) and MB-related (OR = 1.62; CI = 1.44-1.83; < .001) readmissions, but not stroke-related readmission; for MB-related readmissions average LOS and costs were higher for rivaroxaban treated patients. Significant differences in risks of all-cause, MB-related, and stroke-related readmissions were not observed between the apixaban and dabigatran cohorts. In this retrospective real-world analysis of NVAF patients, apixaban treatment was associated with better clinical outcomes than warfarin or rivaroxaban and lower hospital resource burden.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241468 | PMC |
| http://dx.doi.org/10.1080/21556660.2020.1750418 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of Bleeding and Thrombotic Outcomes of Anticoagulation Strategies Upon Intensive Care Unit Admission for Patients with Atrial Fibrillation on Direct Oral Anticoagulants.
J Pharm Pract
September 2025
Department of Pharmacy, Houston Methodist Hospital, TX, USA.
Critically ill adults are more commonly being admitted to intensive care units (ICU) with a recent history of direct oral anticoagulant (DOAC) use. No consensus guidance exists on optimal anticoagulation strategies in critically ill adults with non-valvular atrial fibrillation (NVAF) on DOAC's prior to ICU admission, and there is considerable variability in clinical practice. To evaluate rates of major bleeding and thrombosis between 2 anticoagulation strategies for NVAF upon ICU admission: package insert (continuation of oral or parenteral anticoagulation per manufacturer recommendations) vs non-package insert (prophylactic dosing or delayed therapeutic anticoagulation).
View Article and Find Full Text PDFInteratrial block predicts left atrial appendage thrombus in nonvalvular atrial fibrillation.
J Electrocardiol
September 2025
Department of Cardiology, Ankara City Hospital, Health Sciences University, Ankara, Turkey.
Background: Interatrial block (IAB) is an electrocardiographic manifestation of atrial conduction delay and structural remodeling. While it has been linked to atrial fibrillation (AF) and thromboembolic events, its potential role in predicting left atrial appendage (LAA) thrombus formation remains underexplored. This study aimed to investigate the association between IAB and the presence of LAA thrombus in patients with nonvalvular AF (NVAF) or atrial flutter referred for rhythm control procedures.
View Article and Find Full Text PDFLeft atrial appendage closure in patients with prior intracranial bleeding, safety, efficacy, and timing.
Neurologia (Engl Ed)
September 2025
Hospital Universitario de Salamanca, CIBERCV, IBSAL, Spain.
Background: Oral anticoagulation (OAC) use increases the risk of intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF) and CHADS-VASc ≥2. Left atrial appendage occlusion (LAAO) is an alternative to OAC, however data about its use in patients with prior ICH is scarce and the timing of its performance is controversial. Furthermore, the long-term outcomes in this group of patients have not been described previously.
View Article and Find Full Text PDFSystematic Scoping on Point-of-care Monitoring of Direct Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation: Current Status and Future Perspectives in Malaysia.
Eur Cardiol
August 2025
Clinical Research Centre, Sarawak General Hospital, Institute for Clinical Research, National Institutes of Health Ministry of Health Kuching, Sarawak, Malaysia.
This review explores the use of point-of-care (POC) monitoring of direct oral anticoagulants (DOACs) in patients with non-valvular AF globally and in Malaysia. As patent protection measures for innovative medicines come to an end, and generic alternatives become available, we expect a greater uptake of DOACs than warfarin by patients due to cost advantages. However, the anticoagulation effect of DOACs has been shown to vary from patient to patient and is associated with thrombotic and bleeding risks.
View Article and Find Full Text PDFA new integrated machine learning model: application to improve the accuracy of predicting left atrial appendage thrombus in patients with non-valvular atrial fibrillation.
Front Med (Lausanne)
August 2025
Department of Ultrasonography, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, China.
Background: Non-Valvular Atrial fibrillation (NVAF) and atrial flutter are significant contributors to left atrial appendage thrombus (LAAT) formation. This study explores the potential of machine learning (ML) models integrating transthoracic echocardiography (TTE) and clinical data for non-invasive LAAT detection and risk assessment.
Methods: A total of 698 patients with NVAF was recruited from Luoyang Central Hospital between January 2021 and May 2024, including 558 patients for retrospective analysis and 140 for prospective validation.